IRLAB Therapeutics AB (publ) (IRLAB-A) — Cash Flow-to-Debt Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2025, meaning its operating cash flow of Skr-24.18 Million could theoretically repay 0% of its total liabilities (Skr107.49 Million) in one year. Check IRLAB-A cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
IRLAB Therapeutics AB (publ) Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for IRLAB Therapeutics AB (publ) across 12 annual periods. Also explore how large is IRLAB Therapeutics AB (publ)'s balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for IRLAB Therapeutics AB (publ) (2014–2025)
Year-by-year debt coverage analysis for IRLAB Therapeutics AB (publ). For market capitalisation and broader financial context, see IRLAB Therapeutics AB (publ) (IRLAB-A) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.51x | Skr-55.22 Million | Skr107.49 Million | ▲ +18.9% |
| 2024 | -0.63x | Skr-65.59 Million | Skr103.58 Million | ▲ +76.4% |
| 2023 | -2.69x | Skr-164.85 Million | Skr61.36 Million | ▲ +38.3% |
| 2022 | -4.36x | Skr-142.61 Million | Skr32.72 Million | ▼ -347.2% |
| 2021 | 1.76x | Skr128.64 Million | Skr72.97 Million | ▲ +143.8% |
| 2020 | -4.02x | Skr-89.21 Million | Skr22.19 Million | ▼ -15.7% |
| 2019 | -3.48x | Skr-91.20 Million | Skr26.24 Million | ▲ +38.8% |
| 2018 | -5.68x | Skr-70.79 Million | Skr12.46 Million | ▲ +21.6% |
| 2017 | -7.24x | Skr-57.74 Million | Skr7.97 Million | ▼ -63.7% |
| 2016 | -4.43x | Skr-40.82 Million | Skr9.22 Million | ▼ -45.1% |
| 2015 | -3.05x | Skr-27.66 Million | Skr9.06 Million | ▼ -394.1% |
| 2014 | -0.62x | Skr-11.02 Million | Skr17.86 Million | — |